CMS Open Payments · Program Year 2024
Atlas Spine, Inc.
Atlas Spine, Inc. reported $31,255.86 across General Payments, Research, and Ownership to 17 physicians and teaching hospitals across 17 transactions.
- $31.3K
- All-tracks total
- 17
- Transactions
- 17
- Recipients
- #1463
- of 1,925 companies
Atlas Spine, Inc. reported $31,255.86 across all CMS Open Payments tracks (General + Research + Ownership) to 17 physicians and teaching hospitals in Program Year 2024 - ranking #1463 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $31,255.86, averaging $1.8K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer atlas-spine-inc Atlas Spine, Inc.
$31.3K · #1463/1,925 · 0.0% industry · PY2024
- TOT $31.3K
- RANK #1463
- SHARE 0.0%
- TXN 17
- RCP 17
- CAT 2
- GEN $31.3K
- TOP1 25.9%
- PY 2024
Volume peers
Nearest volume peer: Vitrolife Inc. ($31.3K)
Atlas Spine, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Atlas Spine, Inc.
Atlas Spine, Inc. ranks #1463 out of 1,925 companies in the CMS Open Payments database for Program Year 2024, a comparatively small 0.0% slice of all industry payments reported nationwide for the year. The underlying total is $31,255.86 across 17 transactions to 17 physicians and teaching hospitals - $1.8K per transaction and $1.8K per recipient on average.
"Royalty or License" leads the 2-category general-payment breakdown below at $31.1K (99.5% of General Payments, 16 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
"Royalty or License" leads Atlas Spine, Inc.'s 2-category general-payment breakdown at $31.1K, 99.5% of the reported total.
How Atlas Spine, Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Royalty or License | $31.1K | 16 | 99.5% |
| Food and Beverage | $163.38 | 1 | 0.5% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $31,255.86 (100.0%) of $31,255.86 in this company's General Payments records across 5 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Atlas Spine, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Steven C Ludwig
$8,110.29 across 4 reported transactions
- 2
Alex R Vaccaro
$8,110.29 across 4 reported transactions
- 3
Andrew C Hecht
$8,110.29 across 4 reported transactions
- 4
Brian O'Shaughnessy
$6,761.61 across 4 reported transactions
- 5
Karthik Madhavan
$163.38 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Atlas Spine, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Atlas Spine, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Atlas Spine, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Catheter Precision Inc.
ProgenaCare Global, LLC
Prexion, Inc.
Lupin Inc.
Optos plc
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.